Laurus Labs Announces 40% Interim Dividend for FY2025-26, Stock Rises 2.07% Amid Strong Payout Plan

Mumbai, 23 October 2025: Laurus Labs Limited (NSE: LAURUSLABS, BSE: 540222) has declared an interim dividend of ₹0.80 per equity share, amounting to 40% of the face value of ₹2 for the financial year 2025–26. The Board of Directors approved the dividend at its meeting held today between 2:00 p.m. and 2:55 p.m. The company has set 31 October 2025 as the record date for determining eligible shareholders, with the payout scheduled on or after 12 November 2025.

Headquartered in Hyderabad, Laurus Labs operates in the pharmaceutical and biotechnology sector, specialising in APIs, formulations, and contract research services. Listed on the NSE and BSE under LAURUSLABS, the company has established itself as a key player in India’s pharmaceutical landscape, combining research-driven innovation with robust commercial execution.

Stock Gains 2.07% to ₹943 Following Dividend Declaration, Market Capitalisation Holds at ₹50,500 Crore

As of 3:30 p.m. IST, Laurus Labs’ share price was at ₹943, up ₹19.10 (2.07%) from the previous close. The stock opened at ₹927.40, hitting an intraday high of ₹943.00 and a low of ₹920.70. With a market capitalisation of ₹50,500 crore and a P/E ratio of 99.99, the company maintains a strong market presence. This surge reflects investor recognition of consistent dividend payouts and steady operational performance.

52-Week Performance Highlights Rapid Growth and Long-Term Upside

The stock has demonstrated significant momentum over the past year:

• 52-week high: ₹944.00 (19 September 2025)
• 52-week low: ₹440.45 (24 October 2024)
• Year-to-date gain: ₹322.95, up 52.51%
• One-year absolute change: ₹488.65, up 108.75%

Quarter-on-quarter and year-on-year growth has been supported by the company’s strong pharmaceutical and biotechnology operations, including development and manufacturing of active pharmaceutical ingredients (APIs), formulations, and contract research services.

Dividend Track Record Demonstrates Consistent Shareholder Returns

Laurus Labs has maintained a steady dividend distribution over recent years:

• 9 May 2025: Interim ₹0.80
• 6 November 2024: Interim ₹0.40
• 8 May 2024: Interim ₹0.40
• 2 November 2023: Interim ₹0.40
• 10 May 2023: Interim ₹1.20

The current interim dividend reinforces the company’s commitment to providing consistent returns while balancing reinvestment into growth initiatives.

The interim dividend declaration and steady share price performance underscore Laurus Labs’ operational stability and commitment to consistent shareholder returns. The company’s strategic focus on pharmaceuticals, coupled with strong market capitalisation and disciplined financial management, positions it as a resilient participant in India’s healthcare and biotech sector.

REF: https://www.bseindia.com/xml-data/corpfiling/AttachLive/1a9547c1-5149-4c4d-b4db-5f8b004dc625.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations